Zemaira trial for adults with eosinophilic esophagus
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This Phase 2 study tests Zemaira (an alpha-1 antitrypsin treatment given through an IV) to see if it improves eosinophilic esophagitis (EoE) in adults. You may be able to help researchers learn whether this treatment can reduce EoE activity when standard treatments haven’t worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old when you enroll.
- You must have active EoE confirmed on biopsy (at least 15 eosinophils per high-power field) within about the last 12 weeks.
- You should have tried about 8 weeks of standard EoE care (like PPIs or topical steroids) without enough improvement, or you couldn’t tolerate it.
- Your EoE treatment and diet must stay stable for at least 8 weeks (no dose changes) and during the study.
- You must be able and willing to follow study visits and procedures, and a parent/guardian/legal representative must be able to consent if needed.
- You must not have certain excluded conditions (like active H. pylori infection, specific other GI diseases, bleeding problems, major lab abnormalities, or pregnancy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests EP-104GI in adults with eosinophilic esophagitis (EoE), a condition where certain immune cells cause inflammation in the food pipe. It may help improve symptoms and inflammation, and the study also includes a part where people who do well can switch to the active drug.
This trial tests an intervention meant to improve how well adults with eosinophilic esophagitis (EoE) follow their ongoing treatment plan. It may help you stay on your medicine and get better symptom control by making adherence easier.
This study tests whether a medication called upadacitinib can help people with eosinophilic esophagitis (a condition where too many white blood cells called eosinophils build up in the food tube) who are not getting better with their current steroid treatment. The medication works by reducing inflammation in the esophagus.
This study looks at how eosinophilic inflammation in the esophagus and intestines affects outcomes like symptoms and test findings. It may help clinicians better understand these conditions and track what changes over time.
This study tests a new way to find out which foods are causing your EoE symptoms, so you can avoid only those foods instead of a full elimination diet. It involves a blood test and an endoscopy, and results will help guide your diet plan.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
Hear when a new Eosinophilic Esophagitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.